DK2437726T3 - Formuleringer til behandling af dyb vævssmerte - Google Patents
Formuleringer til behandling af dyb vævssmerte Download PDFInfo
- Publication number
- DK2437726T3 DK2437726T3 DK10742250.3T DK10742250T DK2437726T3 DK 2437726 T3 DK2437726 T3 DK 2437726T3 DK 10742250 T DK10742250 T DK 10742250T DK 2437726 T3 DK2437726 T3 DK 2437726T3
- Authority
- DK
- Denmark
- Prior art keywords
- formulation
- surfactant
- lipid
- edta
- buffer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (13)
1. Vesikulasr formulering til anvendelse i behandlingen af smerte, der hasnger sammen med osteoarthritis, omfattende en eller flere phospholipider og en eller flere ikke-ioniske tensider, og som er fri for ethvert farmaceutisk aktivt stof, der ikke er en lipid eller tensid, hvor formuleringen pafores topisk.
2. Vesikulasr formulering ifolge krav 1 til anvendelse i behandlingen af smerte inklusive dyb vasvssmerte.
3. Vesikulasr formulering ifolge et af de foregaende krav, hvor molforholdet af phospholipid til tensid ligger i omradet fra ca. 1:3 til ca. 30:1, foretrukket ca. 1:1 til ca. 30:1 og mere foretrukket ca. 2:1 til ca. 20:1.
4. Vesikulasr formulering ifolge et af de foregaende krav, hvor formuleringen indeholder 2,0-10,0 v3egt-% phospholipid.
5. Vesikulasr formulering ifolge et af de foregaende krav, hvor den ene eller de flere phospholipider inkluderer phosphatidylcholin.
6. Vesikulasr formulering ifolge et af de foregaende krav, hvor formuleringen indeholder 0,2-5,0 v3egt-% tensid.
7. Vesikulasr formulering ifolge et af de foregaende krav, hvor formuleringen omfatter en eller flere ikke-ioniske tensider udvalgt fra polyoxyethylen-sorbitaner, polyhydroxyethylen-stearater og polyhydroxyethylen-laurylethere.
8. Vesikulasr formulering ifolge et af de foregaende krav, hvor den ene eller flere tensider inkluderer polysorbat 80.
9. Vesikulasr formulering til anvendelse i behandlingen af smerte, der hasnger sammen med osteoarthritis, og som i det vassentlige bestar af en eller flere phospholipider og en eller flere ikke-ioniske tensider i en farmaceutisk acceptabel basrer, hvor formuleringen er topisk pafort.
10. Vesikulasr formulering ifolge krav 10, hvor molforholdet af phospholipid til tensid ligger i omradet fra ca. 1:3 til ca. 30:1, foretrukket ca. 1:1 til ca. 30:1, og mere foretrukket ca. 2:1 til ca. 20:1.
11. Vesikulasr formulering ifolge krav 10 eller krav 11, hvor den ene eller de flere phospholipider inkluderer phosphatidylcholin.
12. Vesikulasr formulering ifolge krav 10, krav 11 eller krav 12, hvor formuleringen omfatter en eller flere ikke-ioniske tensider udvalgt fra polyoxyethylen-sorbitaner, polyhydroxyethylen-stearater og polyhydroxyethylen-laurylethere.
13. Vesikulasr formulering ifolge et af kravene 10 til 13, hvor formuleringen endvidere inkluderer en eller flere buffere, chelatdannere, fugtighedsbevarende midler, smoremidler, antioxidanter, konserveringsmidler, mikrobiocider, antimikrobielle midler, emollienter, cosolventer eller fortykkelsesmidler.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18395609P | 2009-06-03 | 2009-06-03 | |
| US31447810P | 2010-03-16 | 2010-03-16 | |
| US32014810P | 2010-04-01 | 2010-04-01 | |
| PCT/IB2010/001557 WO2010140061A2 (en) | 2009-06-03 | 2010-06-03 | Formulations for the treatment of deep tissue pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2437726T3 true DK2437726T3 (da) | 2018-08-13 |
Family
ID=42785828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10742250.3T DK2437726T3 (da) | 2009-06-03 | 2010-06-03 | Formuleringer til behandling af dyb vævssmerte |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20120220669A1 (da) |
| EP (1) | EP2437726B1 (da) |
| JP (2) | JP2012528846A (da) |
| KR (1) | KR20140021950A (da) |
| CN (4) | CN102639113A (da) |
| AU (1) | AU2010255391C1 (da) |
| BR (1) | BRPI1010861A8 (da) |
| CA (1) | CA2764227C (da) |
| CL (1) | CL2011003065A1 (da) |
| CO (1) | CO6480985A2 (da) |
| DE (1) | DE112010001765T5 (da) |
| DK (1) | DK2437726T3 (da) |
| EA (1) | EA029132B1 (da) |
| ES (1) | ES2682075T3 (da) |
| GB (1) | GB2483419B (da) |
| IL (1) | IL216737A (da) |
| LT (1) | LT2437726T (da) |
| MX (1) | MX349417B (da) |
| MY (1) | MY170121A (da) |
| NZ (1) | NZ597419A (da) |
| PL (1) | PL2437726T3 (da) |
| PT (1) | PT2437726T (da) |
| SG (1) | SG176297A1 (da) |
| WO (1) | WO2010140061A2 (da) |
| ZA (1) | ZA201200017B (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013502436A (ja) * | 2009-08-21 | 2013-01-24 | ターゲッティド デリバリー テクノロジーズ リミテッド | 小胞状の製剤 |
| GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
| GB201206486D0 (en) * | 2012-04-12 | 2012-05-30 | Sequessome Technology Holdings Ltd | Vesicular formulations and uses thereof |
| GB201208384D0 (en) | 2012-05-14 | 2012-06-27 | Sequessome Technology Holdings Ltd | Vesicular formulations, uses and methods |
| GB201208409D0 (en) * | 2012-05-14 | 2012-06-27 | Sequessome Technology Holdings Ltd | Vesicular formulations, kits and uses |
| KR102325654B1 (ko) * | 2013-07-31 | 2021-11-12 | 시퀘솜 네크놀로지 홀딩스 리미티드 | 소포체 |
| GB201417589D0 (en) | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
| GB201505532D0 (en) * | 2015-03-31 | 2015-05-13 | Sequessome Technology Holdings Ltd | Formulations |
| WO2017001617A1 (en) | 2015-06-30 | 2017-01-05 | Sequessome Technology Holdings Limited | Blended formulations |
| GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
| GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
| GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
| CN114507408A (zh) * | 2022-03-02 | 2022-05-17 | 陕西科技大学 | 一种低摩擦、模量可调的物理水凝胶及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6165500A (en) | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
| WO1992003122A1 (de) | 1990-08-24 | 1992-03-05 | Gregor Cevc | Präparat zur wirkstoffapplikation in kleinsttröpfchenform |
| ES2107668T3 (es) * | 1992-07-08 | 1997-12-01 | Dianorm G Maierhofer Gmbh | Liposomas, procedimiento para su preparacion y su uso en la elaboracion de un medicamento. |
| DE4447287C1 (de) | 1994-12-30 | 1996-11-07 | Cevc Gregor | Präparat zum Wirkstofftransport durch Barrieren |
| US5902604A (en) * | 1995-06-06 | 1999-05-11 | Board Of Regents, The University Of Texas System | Submicron liposome suspensions obtained from preliposome lyophilizates |
| CN1322129A (zh) * | 1998-09-01 | 2001-11-14 | 伊迪亚股份公司 | 带电穿透剂通过屏障的电控转运 |
| ES2226203T3 (es) * | 1998-12-23 | 2005-03-16 | Idea Ag | Formulacion mejorada para aplicacion topica no invasiva. |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| TWI281407B (en) * | 2000-09-18 | 2007-05-21 | Vasogen Ireland Ltd | Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| EP1230917A1 (de) * | 2001-02-08 | 2002-08-14 | Vectron Therapeutics AG | Invasomen zur Therapie von Erkrankungen, ihre Herstellung und Verwendung |
| US20040009216A1 (en) * | 2002-04-05 | 2004-01-15 | Rodrigueza Wendi V. | Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
| EP1551370B1 (en) * | 2002-10-11 | 2007-12-19 | Idea Ag | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| JP2004131432A (ja) * | 2002-10-11 | 2004-04-30 | Kumamoto Technology & Industry Foundation | 悪性腫瘍抑制剤 |
| US7473432B2 (en) | 2002-10-11 | 2009-01-06 | Idea Ag | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery |
| CA2524478A1 (en) * | 2003-05-02 | 2004-11-18 | Aronex Pharmaceuticals, Inc. | Lipid platinum complexes and methods of use thereof |
| CN1826123A (zh) * | 2003-07-21 | 2006-08-30 | 瓦索金爱尔兰有限公司 | 急性炎症状态的治疗方法 |
| WO2006086992A2 (en) * | 2005-02-18 | 2006-08-24 | Liplasome Pharma A/S | Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands |
| CA2664944C (en) * | 2006-09-28 | 2016-06-14 | Hadasit Medical Research Services & Development Limited | Use of glycerophospholipids for joint lubrication |
-
2010
- 2010-06-03 AU AU2010255391A patent/AU2010255391C1/en active Active
- 2010-06-03 WO PCT/IB2010/001557 patent/WO2010140061A2/en active Application Filing
- 2010-06-03 MY MYPI2011005823A patent/MY170121A/en unknown
- 2010-06-03 CN CN2010800332740A patent/CN102639113A/zh active Pending
- 2010-06-03 DE DE112010001765T patent/DE112010001765T5/de not_active Ceased
- 2010-06-03 CN CN201510124588.6A patent/CN105434353A/zh active Pending
- 2010-06-03 KR KR1020127000044A patent/KR20140021950A/ko not_active Application Discontinuation
- 2010-06-03 US US13/375,155 patent/US20120220669A1/en not_active Abandoned
- 2010-06-03 CA CA2764227A patent/CA2764227C/en active Active
- 2010-06-03 EA EA201190344A patent/EA029132B1/ru unknown
- 2010-06-03 ES ES10742250.3T patent/ES2682075T3/es active Active
- 2010-06-03 CN CN201510137706.7A patent/CN105434354A/zh active Pending
- 2010-06-03 MX MX2011012754A patent/MX349417B/es active IP Right Grant
- 2010-06-03 CN CN201510129181.2A patent/CN105434329A/zh active Pending
- 2010-06-03 LT LTEP10742250.3T patent/LT2437726T/lt unknown
- 2010-06-03 NZ NZ597419A patent/NZ597419A/en unknown
- 2010-06-03 SG SG2011088671A patent/SG176297A1/en unknown
- 2010-06-03 EP EP10742250.3A patent/EP2437726B1/en active Active
- 2010-06-03 DK DK10742250.3T patent/DK2437726T3/da active
- 2010-06-03 JP JP2012513689A patent/JP2012528846A/ja active Pending
- 2010-06-03 GB GB1122433.4A patent/GB2483419B/en active Active
- 2010-06-03 PL PL10742250T patent/PL2437726T3/pl unknown
- 2010-06-03 BR BRPI1010861A patent/BRPI1010861A8/pt not_active Application Discontinuation
- 2010-06-03 PT PT107422503T patent/PT2437726T/pt unknown
-
2011
- 2011-12-01 IL IL216737A patent/IL216737A/en active IP Right Grant
- 2011-12-02 CL CL2011003065A patent/CL2011003065A1/es unknown
- 2011-12-30 CO CO11181661A patent/CO6480985A2/es not_active Application Discontinuation
-
2012
- 2012-01-03 ZA ZA2012/00017A patent/ZA201200017B/en unknown
-
2015
- 2015-05-20 JP JP2015102360A patent/JP2015193629A/ja active Pending
- 2015-12-16 US US14/971,928 patent/US20160175448A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2437726T3 (da) | Formuleringer til behandling af dyb vævssmerte | |
| US9452179B2 (en) | Vesicular formulations | |
| US20210393655A1 (en) | Vesicular Formulations for Use in the Treatment of Pain or Reduced Mobility of a Joint | |
| US9555051B2 (en) | Vesicular formulations | |
| EP2849721A1 (en) | Vesicular formulations, uses and methods | |
| US20150132349A1 (en) | Vesicular Formulations, Kits and Uses | |
| AU2015202217A1 (en) | Vesicular formulations |